However, visualization of the causal pathways with third factor analysis in the DAG implies that therapies which target MCP-1/CCL2, MAS, and hyperferritinemia all together will be more efficacious than therapies that target any one of these alone. The gene discussed is CCL2; the disease is isolated hyperferritinemia.